Novartis Announces the Planned Acquisition of Advanced Accelerator Applications

Novartis announced that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applications (NASDAQ:AAAP) is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera® (177Lu-DOTATATE), a first-in-class RLT product for neuroendocrine tumors (NETs). Radiopharmaceuticals, such as Lutathera, are unique medicinal formulations containing radioisotopes which are used clinically for both diagnosis and therapy. The transaction would strengthen Novartis' oncology presence with both near-term product launches as well as a new technology platform with potential applications across a number of oncology early development programs.

NANETS2017 Registration Update

Dear NANETS Members and Colleagues,

We are so grateful to everyone interested in attending the 10th Annual NANETS Symposium, October 19-21, 2017 in Philadelphia, PA. We have exceeded last year by over 180 registrants

For the first time ever, the annual NANETS Symposium has SOLD OUT. Due to hotel capacity rules and fire codes we unfortunately cannot accommodate any more registrants, including any walk-up registrations.